Sufugolix - Takeda
Alternative Names: TAK 013Latest Information Update: 30 Jul 2020
At a glance
- Originator Takeda
- Class Antihormones
- Mechanism of Action Gonadotropin releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Endometriosis; Uterine leiomyoma
Most Recent Events
- 31 Aug 2005 Takeda completes a phase-II clinical trials in Endometriosis in United Kingdom (PO) (EudraCT2004-003829-28)
- 29 Jul 2005 Discontinued - Phase-II for Endometriosis in Germany (PO)
- 29 Jul 2005 Discontinued - Phase-II for Endometriosis in United Kingdom (PO) (Takeda pipeline July 2005)